Induction of glutathione synthesis explains pharmacodynamics of high-dose busulfan in mice and highlights putative mechanisms of drug interaction

Drug Metabolism and Disposition

Volumn 35, Issue 2, 2007, Pages 306-314

  Bouligand, Jérôme ^a   Deroussent, Alain ^a   Simonnard, Nicolas ^a   Opolon, Paule ^b   Morizet, Jackie ^a   Connault, Elisabeth ^b   Daudigeos, Estelle ^a   Re, Micheline ^a   Paci, Angelo ^a   Vassal, Gilles ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b CNRS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CYSTEINE; GLUTAMATE CYSTEINE LIGASE; GLUTATHIONE; GLUTATHIONE TRANSFERASE;

ACUTE TOXICITY; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG MEGADOSE; DRUG PROTEIN BINDING; ENZYME ACTIVATION; ENZYME ACTIVITY; FOLLOW UP; GLUTATHIONE METABOLISM; LIVER TOXICITY; MALE; MOUSE; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; PROTEIN INDUCTION;

ANIMALS; BONE MARROW TRANSPLANTATION; BUSULFAN; DRUG INTERACTIONS; GLUTATHIONE; GLUTATHIONE TRANSFERASE; HEPATIC VENO-OCCLUSIVE DISEASE; LIVER; MALE; METABOLIC CLEARANCE RATE; MICE; MICE, INBRED C57BL;

ANIMALIA; MUS;

EID: 33846424934     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.106.012880     Document Type: Article

References (40)

1. Abernathy CO, Hodgson E, and Guthrie FE (1971) Structure-activity relationships on the induction of hepatic microsomal enzymes in the mouse by 1,1,1-trichloro-2,2-bis(pchlorophenyl) ethane(DDT) analogs. Biochem Pharmacol 20:2385-2393.
2. Adinolfi LE, Ingrosso D, Cesaro G, Cimmino A, D'Anto M, Capasso R, Zappia V, and Ruggiero G (2005) Hyperhomocysteinemia and the MTHFR C677T polymorphism promote steatosis and fibrosis in chronic hepatitis C patients. Hepatology 41:995-1003.
3. Belanger PM, Desgagne M, and Bruguerolle B (1991) Temporal variations in microsomal lipid peroxidation and in glutathione concentration of rat liver. Drug Metab Dispos 19:241-244.
4. Boland I, Vassal G, Morizet J, Terrier-Lacombe MJ, Valteau-Couanet D, Kalifa C, Hartmann O, and Gouyette A (1999) Busulphan is active against neuroblastoma and medulloblastoma xenografts in athymic mice at clinically achievable plasma drug concentrations. Br J Cancer 79:787-792.
5. Bouligand J, Boland I, Valteau-Couanet D, Deroussent A, Kalifa C, Hartmann O, and Vassal G (2003) In children and adolescents, the pharmacodynamics of high-dose busulfan is dependent on the second alkylating agent used in the combined regimen (melphalan or thiotepa). Bone Marrow Transplant 32:979-986.
6. Bouligand J, Deroussent A, Morizet J, Paci A, and Vassal G (2006) Liquid chromatography-tandem mass spectrometry assay of reduced and oxidized glutathione and main precursors in mice liver. J Chromatogr B Anal Technol Biomed Life Sci 832:67-74.
7. Bouligand J, Paci A, Mercier L, Vassal G, and Bourget P (2004) High-performance thin-layer chromatography with a derivatization procedure, a suitable method for the identification and the quantitation of busulfan in various pharmaceutical products. J Pharm Biomed Anal 34:525-530.
8. Buttar HS, Chow AY, and Downie RH (1977) Glutathione alterations in rat liver after acute and subacute oral administration of paracetamol. Clin Exp Pharmacol Physiol 4:1-6.
9. Czerwinski M, Gibbs JP, and Slattery JT (1996) Busulfan conjugation by glutathione S-transferases alpha, mu, and pi. Drug Metab Dispos 24:1015-1019.
10. DeLeve LD (1996) Cellular target of cyclophosphamide toxicity in the murine liver: role of glutathione and site of metabolic activation. Hepatology 24:830-837.
11. DeLeve LD, Shulman HM, and McDonald GB (2002) Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease). Semin Liver Dis 22:27-42.
12. DeLeve LD and Wang X (2000) Role of oxidative stress and glutathione in busulfan toxicity in cultured murine hepatocytes. Pharmacology 60:143-154.
13. Down JD, Berman AJ, Warhol M, Van Dijken PJ, Ferrara JL, Yeap B, Hellman S, and Mauch PM (1989) Late tissue-specific toxicity of total body irradiation and busulfan in a murine bone marrow transplant model. Int J Radiat Oncol Biol Phys 17:109-116.
14. Dressel D, Ritter CA, Sperker B, Grube M, Maier T, Klingebiel T, Siegmund W, Beck JF, and Kroemer HK (2003) Busulfan induces activin A expression in vitro and in vivo: a possible link to venous occlusive disease. Clin Pharmacol Ther 74:264-274.
15. Evens AM, Mehta J, and Gordon LI (2004) Rust and corrosion in hematopoietic stem cell transplantation: the problem of iron and oxidative stress. Bone Marrow Transplant 34:561-571.
16. Fernandez-Checa JC and Kaplowitz N (2005) Hepatic mitochondrial glutathione: transport and role in disease and toxicity. Toxicol Appl Pharmacol 204:263-273.
17. Gerecitano J, Mathias C, Mick R, Duffy KM, Luger S, Stadtmauer EA, Schuster SJ, Tsai D, Nasta S, Berlin J, et al. (2003) Homocysteine and prothrombin fragment 1+2 levels in patients with veno-occlusive disease after stem cell transplantation. J Hematother Stem Cell Res 12:215-223.
18. Gibbs JP, Murray G, Risler L, Chien JY, Dev R, and Slattery JT (1997) Age-dependent tetrahydrothiophenium ion formation in young children and adults receiving high-dose busulfan. Cancer Res 57:5509-5516.
19. Gibbs JP, Yang JS, and Slattery JT (1998) Comparison of human liver and small intestinal glutathione S-transferase-catalyzed busulfan conjugation in vitro. Drug Metab Dispos 26:52-55.
20. Griffith OW (1999) Biologic and pharmacologic regulation of mammalian glutathione synthesis. Free Radic Biol Med 27:922-935.
21. Hartmann O, Benhamou E, Beaujean F, Pico JL, Kalifa C, Patte C, Flamant F, and Lemerle J (1986) High-dose busulfan and cyclophosphamide with autologous bone marrow transplantation support in advanced malignancies in children: a phase II study. J Clin Oncol 4:1804-1810.
22. Hassan M and Ehrsson H (1987) Urinary metabolites of busulfan in the rat. Drug Metab Dispos 15:399-402.
23. Hassan M, Ljungman P, Ringden O, Hassan Z, Oberg G, Nilsson C, Bekassy A, Bielenstein M, Abdel-Rehim M, Georen S, et al. (2000) The effect of busulphan on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite: time interval influence on therapeutic efficacy and therapy-related toxicity. Bone Marrow Transplant 25:915-924.
24. Lafaye A, Junot C, Pereira Y, Lagniel G, Tabet JC, Ezan E, and Labarre J (2005) Combined proteome and metabolite-profiling analyses reveal surprising insights into yeast sulfur metabolism. J Biol Chem 280:24723- 24730.
25. Lee JI, Londono M, Hirschberger LL, and Stipanuk MH (2004) Regulation of cysteine dioxygenase and gamma-glutamylcysteine synthetase is associated with hepatic cysteine level. J Nutr Biochem 15:112-122.
26. McDonald GB, Hinds MS, Fisher LD, Schoch HG, Wolford JL, Banaji M, Hardin BJ, Shulman HM, and Clift RA (1993) Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med 118:255-267.
27. Meresse V, Hartmann O, Vassal G, Benhamou E, Valteau-Couanet D, Brugieres L, and Lemerle J (1992) Risk factors for hepatic veno-occlusive disease after high-dose busulfan-containing regimens followed by autologous bone marrow transplantation: a study in 136 children. Bone Marrow Transplant 10:135-141.
28. Motohashi H and Yamamoto M (2004) Nrf2-Keap1 defines a physiologically important stress response mechanism. Trends Mol Med 10:549-557.
29. Park S and Imlay JA (2003) High levels of intracellular cysteine promote oxidative DNA damage by driving the fenton reaction. J Bacteriol 185:1942-1950.
30. Peters WP, Henner WD, Grochow LB, Olsen G, Edwards S, Stanbuck H, Stuart A, Gockerman J, Moore J, and Bast RCJ (1987) Clinical and pharmacologic effects of high dose single agent busulfan with autologous bone marrow support in the treatment of solid tumors. Cancer Res 47:6402-6406.
31. Richman PG and Meister A (1975) Regulation of gamma-glutamyl-cysteine synthetase by nonallosteric feedback inhibition by glutathione. J Biol Chem 250:1422-1426.
32. Ritter CA, Bohnenstengel F, Hofmann U, Kroemer HK, and Sperker B (1999) Determination of tetrahydrothiophene formation as a probe of in vitro busulfan metabolism by human glutathione S-transferase A1-1: use of a highly sensitive gas chromatographic-mass spectrometric method. J Chromatogr B Biomed Sci Appl 730:25-31.
33. Ritter CA, Sperker B, Grube M, Dressel D, Kunert-Keil C, and Kroemer HK (2002) Overexpression of glutathione S-transferase A1-1 in ECV 304 cells protects against busulfan mediated G2-arrest and induces tissue factor expression. Br J Pharmacol 137:1100-1106.
34. Santos GW, Tutschka PJ, Brookmeyer R, Saral R, Beschorner WE, Bias WB, Braine HG, Burns WH, Elfenbein GJ, and Kaizer H (1983) Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. N Engl J Med 309:1347-1353.
35. Shulman HM, Luk K, Deeg HJ, Shuman WB, and Storb R (1987) Induction of hepatic veno-occlusive disease in dogs. Am J Pathol 126:114-125.
36. Srivastava A, Poonkuzhali B, Shaji RV, George B, Mathews V, Chandy M, and Krishnamoorthy R (2004) Glutathione S-transferase M1 polymorphism: a risk factor for hepatic venoocclusive disease in bone marrow transplantation. Blood 104:1574-1577.
37. Tsuji Y (2005) JunD activates transcription of the human ferritin H gene through an antioxidant response element during oxidative stress. Oncogene 24:7567-7578.
38. Vassal G, Challine D, Koscielny S, Hartmann O, Deroussent A, Boland I, Valteau-Couanet D, Lemerle J, Levi F, and Gouyette A (1993) Chronopharmacology of high-dose busulfan in children. Cancer Res 53:1534-1537.
39. Vassal G, Re M, and Gouyette A (1988) Gas chromatographic-mass spectrometric assay for busulfan in biological fluids using a deuterated internal standard. J Chromatogr 428:357-361.
40. Wallin B, Rosengren B, Shertzer HG, and Camejo G (1993) Lipoprotein oxidation and measurement of thiobarbituric acid reacting substances formation in a single microtiter plate: its use for evaluation of antioxidants. Anal Biochem 208:10-15.